NCT03521960View on ClinicalTrials.gov

Buspirone for Opioid Tapering

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Opioid-Related DisordersDependency (Psychology)Pain, ChronicOpiate Withdrawal Syndrome
Interventions
DRUG

Buspirone oral capsule

15 milligrams, three times daily

DRUG

Placebo oral capsule

0 milligrams (placebo), three times daily

Trial Locations (1)

21205

Johns Hopkins University, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT03521960 - Buspirone for Opioid Tapering | Biotech Hunter | Biotech Hunter